Hypertension_NN
in_IN
pregnancy_NN
._.

Pregnancy-induced_JJ
hypertension_NN
-LRB-_-LRB-
PIH_NN
-RRB-_-RRB-
is_VBZ
a_DT
frequent_JJ
cause_NN
of_IN
maternal_JJ
and_CC
neonatal_JJ
morbidity_NN
and_CC
mortality_NN
._.

In_IN
the_DT
present_JJ
study_NN
we_PRP
focused_VBD
on_IN
the_DT
pathophysiology_NN
of_IN
PIH_NN
,_,
mainly_RB
on_IN
the_DT
role_NN
of_IN
mineralocorticoids_NNS
,_,
reversed_VBN
blood_NN
pressure_NN
patterns_NNS
,_,
and_CC
the_DT
resulting_VBG
necessity_NN
of_IN
continuous_JJ
monitoring_NN
of_IN
the_DT
preeclamptic_JJ
mother_NN
._.

Problems_NNS
of_IN
antihypertensive_JJ
therapy_NN
are_VBP
discussed_VBN
and_CC
the_DT
first_JJ
results_NNS
of_IN
a_DT
pilot_NN
study_NN
with_IN
Urapidil_NN
are_VBP
presented_VBN
._.

To_TO
examine_VB
the_DT
role_NN
of_IN
mineralocorticoids_NNS
in_IN
the_DT
pathophysiology_NN
of_IN
PIH_NN
,_,
we_PRP
studied_VBD
plasma_NN
aldosterone_NN
and_CC
18-hydroxy-corticosterone_NN
-LRB-_-LRB-
18-OH-B_NN
-RRB-_-RRB-
levels_NNS
in_IN
25_CD
women_NNS
with_IN
PIH_NN
and_CC
in_IN
25_CD
healthy_JJ
pregnant_JJ
women_NNS
._.

Furthermore_RB
,_,
we_PRP
evaluated_VBD
the_DT
mineralocorticoid_NN
receptor_NN
-LRB-_-LRB-
MR_NN
-RRB-_-RRB-
count_NN
in_IN
mononuclear_JJ
leukocytes_NNS
in_IN
the_DT
2_CD
groups_NNS
._.

The_DT
MR-count_NN
was_VBD
significantly_RB
decreased_VBN
in_IN
the_DT
PIH-group_NN
._.

The_DT
values_NNS
of_IN
plasma_NN
aldosterone_NN
and_CC
18-OH-B_NN
were_VBD
also_RB
low_JJ
._.

These_DT
results_NNS
can_MD
not_RB
be_VB
explained_VBN
by_IN
receptor_NN
down-regulation_NN
due_JJ
to_TO
higher_JJR
level_NN
of_IN
mineralocorticoids_NNS
of_IN
the_DT
zona_NN
glomerulosa_NN
._.

Perhaps_RB
deoxycorticosterone_NN
or_CC
a_DT
hitherto_RB
unknown_JJ
mineralocorticoid_NN
is_VBZ
responsible_JJ
for_IN
the_DT
hypertension_NN
and_CC
altered_JJ
MR-status_NN
._.

The_DT
first_JJ
results_NNS
of_IN
continuous_JJ
blood_NN
pressure_NN
measurements_NNS
with_IN
a_DT
noninvasive_JJ
,_,
real-time_JJ
blood_NN
pressure_NN
monitor_NN
-LRB-_-LRB-
Finapres_NN
-RRB-_-RRB-
are_VBP
presented_VBN
._.

The_DT
comparison_NN
of_IN
the_DT
obtained_VBN
values_NNS
with_IN
intraarterial_JJ
measurements_NNS
demonstrates_VBZ
a_DT
good_JJ
correlation_NN
between_IN
the_DT
two_CD
methods_NNS
._.

We_PRP
also_RB
report_VBP
on_IN
the_DT
first_JJ
experiences_NNS
with_IN
Urapidil_NN
in_IN
the_DT
treatment_NN
of_IN
hypertension_NN
in_IN
severe_JJ
preeclampsia_NN
._.

The_DT
data_NNS
show_VBP
that_IN
hypertension_NN
in_IN
preeclamptic_JJ
women_NNS
can_MD
be_VB
treated_VBN
by_IN
Urapidil_NN
without_IN
side_JJ
effects_NNS
or_CC
reflex-tachycardia_NN
._.

Further_JJ
studies_NNS
will_MD
have_VB
to_TO
prove_VB
if_IN
Urapidil_NN
is_VBZ
suited_VBN
for_IN
prepartal_JJ
treatment_NN
of_IN
PIH_NN
as_RB
well_RB
._.

